Finch Therapeutics Group, Inc. (FNCH)
- Previous Close
1.8800 - Open
1.8800 - Bid --
- Ask --
- Day's Range
1.8800 - 1.9900 - 52 Week Range
1.8600 - 16.7400 - Volume
15,628 - Avg. Volume
53,250 - Market Cap (intraday)
3.115M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-9.8100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
www.finchtherapeutics.comRecent News: FNCH
Performance Overview: FNCH
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FNCH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FNCH
Valuation Measures
Market Cap
3.02M
Enterprise Value
8.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.19
Price/Book (mrq)
0.13
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.93%
Return on Equity (ttm)
-62.64%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.28M
Diluted EPS (ttm)
-9.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
20.76M
Total Debt/Equity (mrq)
155.28%
Levered Free Cash Flow (ttm)
-19.19M
Research Analysis: FNCH
Company Insights: FNCH
FNCH does not have Company Insights